AI Score

Unlock

ARS Pharmaceuticals Inc. (SPRY)

AI Score

Unlock

12.90

0.54 (4.37%)

At close: Mar 24, 2025, 3:59 PM

12.77

-1.01%

After-hours: Mar 24, 2025, 07:57 PM EDT

4.37% (1D)

Bid	12.5
Market Cap	1.25B
Revenue (ttm)	89.38M
Net Income (ttm)	8.02M
EPS (ttm)	0.08
PE Ratio (ttm)	161.28
Forward PE	-41.62
Analyst	Buy

Ask	13.05
Volume	1,940,532
Avg. Volume (20D)	1,511,850
Open	12.54
Previous Close	12.36
Day's Range	12.07 - 12.99
52-Week Range	7.55 - 18.51
Beta	1.41

About SPRY

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 4, 2020

Employees 155

Stock Exchange NASDAQ

Ticker Symbol SPRY

Website https://ars-pharma.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 124.76% from the latest price.

Stock Forecasts

Earnings Surprise

ARS Pharmaceuticals has released their quartely earnings on Mar 20, 2025:

Revenue of $86.6M exceeds estimates by $70.7M, with Infinity% YoY growth.

EPS of 0.48 exceeds estimates by 0.60, with 785.71% YoY growth.

Next Earnings Release

ARS Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 days ago

+22.83%

ARS Pharmaceuticals shares are trading higher. The... Unlock content with Pro Subscription

4 months ago

-15.23%

ARS Pharmaceuticals shares are trading lower after the company reported better-than-expected Q3 sales results.

News

4 days ago · seekingalpha.com

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's co...

4 days ago · seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, Presiden...

4 days ago · investors.com

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.

Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.

4 days ago · zacks.com

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year...

1 month ago · seekingalpha.com

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy's early sales also beat expectations, which I think showcases how mu...

2 months ago · investors.com

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.